• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 10
  3. Authors

Online ISSN: 2515-8260

Volume7, Issue10

Direct Acting Antiviral and Glycemic Control In Patients with Hepatitis C

    Asmaa K Ahmed Shereen G Samy Asmaa A Mohammed Alshymaa A. Hassnine M. Elsayed Maysa A. Arandaz

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 10, Pages 1426-1435

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background sustained virological response (SVR) can be achieved in high percentage of HCV patients with the availability of direct acting antiviral agents DAAs. However, the effect of DAAs on insulin resistance and glycemic control has to be clearly documented in patients with HCV infection and type 2diabtes mellitus.
We hypothesize that treatment of HCV with novel direct-acting antiviral medications may have effect on glycemic control and decreased requirement for DM-modulating medications at the time of SVR.
Patients and methods: the present study involved 50 patients with Chronic HCV attended to outpatient hepatology clinic of One Day Surgery Hospital for treatment with DAAs. Measurement of HbA1c, FPG, fasting insulin hormone, c-peptide and calculation of HOMA-IR before and 3 months after DDAs therapy is done.
Statistical analysis was done for these data. Results : After achievement of SVR; HbA1c decreased from 9.57±1.39 to 7.22 ± 0.7 in diabetic patients, HOMA-IR decreased significantly also there was a significant improvement of lipid profile after completion of therapy.
Conclusion: This study showed that eradication of HCV by DAAs cause a parallel decrease in IR and improve glycemic control in patients with established T2DM.
Keywords:
    HCV hepatitis c virus DAA direct acting antivirus DM diabetes mellitus
  • PDF (327 K)
  • XML
(2021). Direct Acting Antiviral and Glycemic Control In Patients with Hepatitis C. European Journal of Molecular & Clinical Medicine, 7(10), 1426-1435.
Asmaa K Ahmed; Shereen G Samy; Asmaa A Mohammed; Alshymaa A. Hassnine; M. Elsayed; Maysa A. Arandaz. "Direct Acting Antiviral and Glycemic Control In Patients with Hepatitis C". European Journal of Molecular & Clinical Medicine, 7, 10, 2021, 1426-1435.
(2021). 'Direct Acting Antiviral and Glycemic Control In Patients with Hepatitis C', European Journal of Molecular & Clinical Medicine, 7(10), pp. 1426-1435.
Direct Acting Antiviral and Glycemic Control In Patients with Hepatitis C. European Journal of Molecular & Clinical Medicine, 2021; 7(10): 1426-1435.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 173
  • PDF Download: 278
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus